Skip to main content

Table 1 Characteristics of malignant glioma cell line reported in 212 included studies

From: Temozolomide sensitivity of malignant glioma cell lines – a systematic review assessing consistencies between in vitro studies

Characteristics Overall
N = 212
Year of publication
Before 2015
N = 72
2015-2017
N = 63
2018 or after
N = 77
Type of cell line
 Human glioma cell line(s) 193 (91.1%) 65 (90.3%) 57 (90.5%) 71 (92.2%)
 Murine glioma cell line(s) 23 (10.8%) 5 (6.9%) 6 (9.5%) 12 (15.4%)
 Patient-derived cell line(s) 22 (10.4%) 9 (12.5%) 7 (11.1%) 6 (7.7%)
Number of cell lines used
 One 48 (22.6%) 14 (19.4%) 15 (23.8%) 19 (24.7%)
 Two 74 (34.9%) 19 (26.4%) 26 (41.3%) 29 (37.7%)
 Three or more 90 (42.5%) 39 (54.2%) 22 (34.9%) 29 (37.7%)
Ten commonest cell lines
 U87 129 (60.4%) 47 (65.3%) 37 (58.7%) 44 (57.1%)
 U251 87 (41.0%) 24 (33.3%) 31 (49.2%) 33 (41.6%)
 T98G 56 (26.4%) 25 (34.7%) 11 (17.5%) 20 (26.0%)
 A172 29 (13.7%) 8 (11.1%) 11 (17.5%) 10 (13.0%)
 U373 27 (12.7%) 15 (20.8%) 6 (9.5%) 6 (7.8%)
 U138 26 (12.3%) 15 (20.8%) 6 (9.5%) 5 (6.5%)
 LN229 22 (10.4%) 7 (9.7%) 4 (6.3%) 11 (14.3%)
 C6 20 (9.4%) 5 (6.9%) 6 (9.5%) 9 (11.7%)
 LN18 13 (6.6%) 6 (8.3%) 2 (3.2%) 5 (6.5%)
 U118 14 (6.6%) 5 (6.9%) 5 (7.9%) 4 (5.2%)